MedTrace Logo

Phase I Study of Hemay102 in Patients With Advanced Solid Tumors

NCT03982303 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2021-10-01

No results posted yet for this study

Summary

This trial was a single-center, open-label, dose-increasing Phase I clinical study with subjects enrolled in patients with advanced solid tumors who failed standard treatment or who were unable to receive effective treatment. The trial is divided into two stages: dose escalation and dose extension.

Conditions

  • Patients With Advanced Stage Solid Tumors

Interventions

DRUG

Hemay102

Hemay102 was administered through i.v. infusion for 4hrs.

Sponsors & Collaborators

  • Tianjin Hemay Oncology Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Ti Zhang, Ph.D. · Tianjing medical university cancer hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-03
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03982303 on ClinicalTrials.gov